newsfilter
← Latest News
GlobeNewswire·

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer

AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)]